BUSINESS

Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan

April 1, 2020
Fujifilm Toyama Chemical officially announced the launch of a Japanese PIII clinical trial for its anti-flu drug Avigan (favipiravir) on March 31 for the treatment of the novel coronavirus disease COVID-19, aiming to enroll some 100 patients and complete the…

To read the full story

Related Article

BUSINESS

By Sakura Kono

Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…

A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Philip Carrigan

In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…